Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Zegerid sales force

This article was originally published in The Tan Sheet

Executive Summary

Santarus looks to build commercial presence for its proton pump inhibitor Zegerid with a sales force expansion announced Oct. 24. Santarus and Schering-Plough announced plans to switch the product from Rx to OTC earlier this month (1"The Tan Sheet" Oct. 23, 2006, p. 3). Approximately 150 sales representatives are expected to be added to the team, which will bring the total number of first detail sales reps to over 500, the firm says. Weekly prescriptions have been growing by 135% since the launch of Zegerid capsules, according to President and CEO Gerals Proehl. "Moreover, our experience indicates that the frequency in delivering a consistent message about Zegerid's clinical benefits is key to increasing awareness and positively impacting physician prescribing behavior," he added. The new sales reps are anticipated to be trained and in place by the end of the first quarter of 2007, with the help of a contract sales organization...

Related Content





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts